Redirecting to https://www.prnewswire.com/apac/news-releases/the-snda-for-sacituzumab-tirumotecan-sac-tmt-in-combination-with-pembrolizumab-as-firstline-treatment-for-pd-l1-positive-nsclc-accepted-for-review-by-nmpa-302766871.html